化学信息:
化学名 | (2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol | |
简称 | Ipragliflozin | |
别名 |
ASP1941, ASP 1941, ASP-1941 |
|
中文名 | N/A | |
化学式 | C21H21FO5S | |
分子量 | 404.45 | |
CAS号 | 761423-87-4 | |
纯度 | 98% | |
溶剂/溶解度 |
Water<1mg/ml; DMSO5mg/ml; Ethanol<1mg/ml |
|
溶液配制 | 5mg加入1.24ml DMSO,或者每4.04mg加入1ml DMSO,配制成10mM溶液。SF9015-10mM用DMSO配制。 |
生物信息:
产品描述 | Ipragliflozin (ASP1941) is a highly potent and selective SGLT2 inhibitor with IC50 of 2.8nM; little and NO potency for SGLT1/3/4/5/6. | ||||
信号通路 | Transmembrane Transporters | ||||
靶点 | SGLT2 | - | - | - | - |
IC50 | 2.8nM | - | - | - | - |
体外研究 | Ipragliflozin potently and selectively inhibited human, rat, and mouse SGLT2 at nanomolar ranges and exhibited stability against intestinal glucosidases. | ||||
体内研究 | Ipragliflozin showed good pharmacokinetic properties following oral dosing, and dose-dependently increased urinary glucose excretion, which lasted for over 12h in normal mice. Oral administration of ipragliflozin increased urinary glucose excretion in a dose-dependent manner, an effect which was significant at doses of 0.3mg/kg or higher and lasted over 12h. Single administration of ipragliflozin dose-dependently increased urinary glucose excretion, reduced blood glucose and plasma insulin levels, and improved glucose intolerance. | ||||
临床实验 | N/A | ||||
特征 | N/A |
相关实验数据(此数据来自于公开文献,碧云天并不保证其有效性):
酶活性检测实验 | |
方法 | N/A |
细胞实验 | |
细胞系 | N/A |
浓度 | N/A |
处理时间 | N/A |
方法 | N/A |
动物实验 | |
动物模型 | N/A |
配制 | N/A |
剂量 | N/A |
给药方式 | N/A |
产品编号 | 产品名称 | 包装 |
SF9015-10mM | Ipragliflozin (SGLT2抑制剂) | 10mM×0.2ml |
SF9015-5mg | Ipragliflozin (SGLT2抑制剂) | 5mg |
SF9015-25mg | Ipragliflozin (SGLT2抑制剂) | 25mg |
— | 说明书 | 1份 |
保存条件:
-20℃保存,至少一年有效。5mg和25mg包装也可室温保存,至少6个月有效。如果溶于非DMSO溶剂,建议分装后-80℃保存,预计6个月内有效。